Abbott Laboratories $ABT Position Lowered by Canada Post Corp Registered Pension Plan

Canada Post Corp Registered Pension Plan reduced its holdings in Abbott Laboratories (NYSE:ABT) by 3.3% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 153,326 shares of the healthcare product maker’s stock after selling 5,182 shares during the quarter. Canada Post Corp Registered Pension Plan’s holdings in Abbott Laboratories were worth $13,913,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories during the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ABT shares. Oppenheimer dropped their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Sanford C. Bernstein decreased their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Wells Fargo & Company raised their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Jefferies Financial Group lowered their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, UBS Group dropped their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $118.67.

Abbott Laboratories Stock Down 0.0%

ABT stock opened at $111.27 on Friday. The stock has a market capitalization of $192.53 billion, a price-to-earnings ratio of 36.01, a PEG ratio of 2.15 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business’s fifty day moving average price is $97.67 and its two-hundred day moving average price is $99.83. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.